ELTP — ELITE PHARMACEUTICALS INC /NV/
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1053369 ·
Last close
$0.26
Market Cap
$280.06M
52W High
$0.69
52W Low
$0.24
ADV30
956,350
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 32,355,283 | 13,507,545 | 7,529,281 | 5,910,565 | 139,669,132 | 38,940,138 | 34,843,076 |
| Mar 2026 | 40,748,067 | 20,772,157 | 11,033,800 | 18,461,188 | 138,289,840 | 29,797,800 | 39,406,865 |
| Dec 2025 | 31,589,251 | 12,953,175 | 9,012,943 | 18,593,806 | 126,412,637 | 21,094,904 | 46,098,554 |
| Sep 2025 | 36,321,704 | 14,073,033 | 8,213,746 | 13,702,407 | 117,247,811 | 26,617,346 | 55,662,843 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$23,748,094
Investing CF
$-925,626
Financing CF
$-4,322,309
CapEx
$-925,626
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,831,240
Inventory
$21,259,898
Receivables
$59,715,676
ST Investments
—
EBIT TTM
$57,211,148
Pretax Income TTM
$56,814,484
Interest Exp TTM
$396,664
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$141,014,304
EBITDA
$37,310,520
Free Cash Flow
$23,001,620
Enterprise Value
$249,919,312
Total Cash
$38,940,136
Total Debt
$5,572,569
Shares Out
1,077,136,442
Trailing EPS
$0.05
Book Value
$0.10
ROE
74.3%
ROA
17.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 148,870,119 | 49,960,196 | 44,872,686 | 138,289,840 | 39,406,865 | 98,882,975 | 23,748,094 |
| Mar 2025 | 84,043,929 | 21,203,894 | -4,314,659 | 96,387,477 | 42,872,448 | 53,515,029 | 7,455,639 |
| Mar 2024 | 56,625,128 | 10,788,769 | 20,108,631 | 83,653,536 | 26,070,718 | 57,582,818 | -3,235,115 |
| Mar 2023 | 34,155,114 | 3,968,809 | 3,561,846 | 40,896,018 | 11,935,758 | 28,960,260 | 3,338,704 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMRN | AMARIN CORP PLC\UK | $278.82M | $13.20 | — |
| IFRX | InflaRx N.V. | $278.53M | $1.89 | — |
| IMRX | Immuneering Corp | $276.26M | $4.27 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $284.87M | $2.60 | — |
| FULC | Fulcrum Therapeutics, Inc. | $285.35M | $3.74 | — |
News headlines (Yahoo Finance, 1h cache)
ELTP Downgraded to Neutral on Pricing Pressure & Limited Visibility
2026-09-10 16:53 · Yahoo
Elite Pharmaceuticals Inc (ELTP) (Q1 2027) Earnings Call Highlights: Steady Revenue and ...
2026-08-18 01:08 · Yahoo
Elite Pharmaceuticals Q1 Earnings Call Highlights
2026-08-14 19:02 · Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
2026-08-13 20:11 · Yahoo
Elite Pharmaceuticals Inc (ELTP) Q4 2026 Earnings Call Highlights: Record Revenue Growth and ...
2026-07-01 01:00 · Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information
2026-06-29 20:29 · Yahoo
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
2026-08-25 15:20 · Yahoo
Possible Generic Drug Tariffs and 2 Microcaps
2026-07-31 06:08 · Yahoo
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
2026-07-15 15:22 · Yahoo
Elite Pharmaceuticals Stock Plunges Post Q1 Earnings, Revenues Fall Y/Y
2026-08-19 17:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.